Critical Demand

Proprietary Product Portfolio

Our first products are CS-TATI-1 and CS-S/BCC-1, targeting HIV and cancer, respectively. These products are still under development, but there has been exciting progress. Our product portfolio will soon be available with more information, so please check back often.